Physician profile
Samar Boulos
NPI 1689067829
$1,844.69
in general payments reported to CMS, 2019-2025
19 companies · $577 in 2025
The $577 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.33 · 2022: $166 · 2023: $458 · 2024: $598 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $494.60 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $331.84 | 2023-2025 | Ozempic, Wegovy |
| Alkermes, INC. | $162.67 | 2023-2025 | Vivitrol, Vivitrol |
| Merck Sharp & Dohme LLC | $123.43 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Otsuka America Pharmaceutical, INC. | $105.89 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Exact Sciences Corporation | $89.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $84.35 | 2023-2025 | |
| Abbvie INC. | $73.28 | 2023-2024 | Vraylar |
| Axsome Therapeutics, INC. | $73.26 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $65.93 | 2019-2024 | Trelegy Ellipta |
| Abbott Laboratories | $35.29 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $34.72 | 2022-2023 | Basaglar, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $34.24 | 2025 | Uzedy |
| Bayer Healthcare Pharmaceuticals INC. | $29.04 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $24.37 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $22.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.82 | 2023 | Jardiance |
| Sanofi Pasteur INC. | $20.70 | 2022 | |
| Nestle Healthcare Nutrition INC. | $18.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Boulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.